Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · IEX Real-Time Price · USD
29.57
+1.07 (3.75%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Aerovate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Selling, General & Admin
17.1914.628.040.950.22
Research & Development
64.2238.6214.997.943.11
Operating Expenses
81.4153.2423.028.893.33
Operating Income
-81.41-53.24-23.02-8.89-3.33
Interest Expense / Income
0000.080
Other Expense / Income
-5.94-1.75-0.060.65-0
Pretax Income
-75.47-51.49-22.96-9.61-3.33
Income Tax
0.060.03000
Net Income
-75.52-51.51-22.96-9.61-3.33
Shares Outstanding (Basic)
26241201
Shares Outstanding (Diluted)
26241201
Shares Change
7.60%99.06%4975.15%-67.70%-
EPS (Basic)
-2.87-2.10-1.87-40.31-4.44
EPS (Diluted)
-2.87-2.10-1.87-40.31-4.44
Free Cash Flow
-56.92-39.32-27.58-7.86-2.78
Free Cash Flow Per Share
-2.16-1.61-2.24-32.44-3.71
EBITDA
-75.37-51.42-22.95-9.54-3.33
Depreciation & Amortization
0.10.070.0200
EBIT
-75.47-51.49-22.96-9.54-3.33
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).